TY - JOUR
T1 - Bumped kinase inhibitor 1294 treats established toxoplasma gondii infection
AU - Doggett, J. Stone
AU - Ojo, Kayode K.
AU - Fan, Erkang
AU - Maly, Dustin J.
AU - Van Voorhis, Wesley C.
PY - 2014/6
Y1 - 2014/6
N2 - Toxoplasma gondii is a unicellular parasite that causes severe brain and eye disease. Current drugs for T. gondii are limited by toxicity. Bumped kinase inhibitors (BKIs) selectively inhibit calcium-dependent protein kinases of the apicomplexan pathogens T. gondii, cryptosporidia, and plasmodia. A lead anti-Toxoplasma BKI, 1294, has been developed to be metabolically stable and orally bioavailable. Herein, we demonstrate the oral efficacy of 1294 against toxoplasmosis in vivo.
AB - Toxoplasma gondii is a unicellular parasite that causes severe brain and eye disease. Current drugs for T. gondii are limited by toxicity. Bumped kinase inhibitors (BKIs) selectively inhibit calcium-dependent protein kinases of the apicomplexan pathogens T. gondii, cryptosporidia, and plasmodia. A lead anti-Toxoplasma BKI, 1294, has been developed to be metabolically stable and orally bioavailable. Herein, we demonstrate the oral efficacy of 1294 against toxoplasmosis in vivo.
UR - http://www.scopus.com/inward/record.url?scp=84901277406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901277406&partnerID=8YFLogxK
U2 - 10.1128/AAC.01823-13
DO - 10.1128/AAC.01823-13
M3 - Article
C2 - 24687502
AN - SCOPUS:84901277406
SN - 0066-4804
VL - 58
SP - 3547
EP - 3549
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 6
ER -